Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is designed to evaluate if self-inserted intravaginal 2% lidocaine gel is effective at decreasing pain during intrauterine device insertion in nulliparous women.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Society of Family Planning
• Treatments: Lidocaine

Criteria

Inclusion criteria:

• Nulliparous, as defined in this study as no history of pregnancy ≥ 24 weeks gestational age

• Desires insertion of either levonorgestrel-releasing IUD (LNG-IUD) or copper T380A IUD (Cu-IUD)

• No history of pregnancy in the last 6 weeks

• Able to provide written informed consent in English and comply with all study procedures

Exclusion criteria:

• Known allergy or hypersensitivity to lidocaine or other amino amide local anesthetics

• Prior failed IUD insertion

• Prior IUD use

• Use of narcotic or benzodiazepine medication within the last 24 hours

• U.S. Centers for Disease Control Medical Eligibility Criteria (MEC) category 3 or 4 classification for use of an IUD

• Positive pregnancy test or reasonable risk of pregnancy due to unprotected heterosexual intercourse since the last menstrual period